Serevent
Product Images NDC 68258-8961

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Serevent (NDC 68258-8961). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Salmeterol Xinafoate Chemical Structure (42aa9a5a C1f5 41ae Ba72 E9a46db63786 01)

Salmeterol Xinafoate Chemical Structure (42aa9a5a C1f5 41ae Ba72 E9a46db63786 01)
FDA Label Image

Figure 1. Serial 12-hour Fev1 From Two 12-week Clinical Trials In Patients With Asthma First Treatment Day (42aa9a5a C1f5 41ae Ba72 E9a46db63786 02)

Figure 1. Serial 12-hour Fev1 From Two 12-week Clinical Trials In Patients With Asthma First Treatment Day (42aa9a5a C1f5 41ae Ba72 E9a46db63786 02)
FDA Label Image

Last Treatment Day (week 12) (42aa9a5a C1f5 41ae Ba72 E9a46db63786 03)

Last Treatment Day (week 12) (42aa9a5a C1f5 41ae Ba72 E9a46db63786 03)
FDA Label Image

Figure 2. Cumulative Incidence Of Asthma-related Deaths In The 28-week Salmeterol Multi-center Asthma Research Trial (smart), By Duration Of Treatment (42aa9a5a C1f5 41ae Ba72 E9a46db63786 04)

Figure 2. Cumulative Incidence Of Asthma-related Deaths In The 28-week Salmeterol Multi-center Asthma Research Trial (smart), By Duration Of Treatment (42aa9a5a C1f5 41ae Ba72 E9a46db63786 04)
FDA Label Image

Figure 3. Mean Percent Change From Baseline In Postdose Fev1 Integrated Data From 2 Trials Of Patients With Chronic Bronchitis And Airflow Limitation (42aa9a5a C1f5 41ae Ba72 E9a46db63786 05)

Figure 3. Mean Percent Change From Baseline In Postdose Fev1 Integrated Data From 2 Trials Of Patients With Chronic Bronchitis And Airflow Limitation (42aa9a5a C1f5 41ae Ba72 E9a46db63786 05)
This text appears to be a medication dosage instruction for SEREVENTDISKUS. It suggests taking 50mg of the medication twice a day. There is also some mention of a baseline FEV and placebo, possibly indicating the medication's efficacy compared to a control group. The word "Endpoint" is also present, but it is unclear what it refers to without further context.*
FDA Label Image

Figure 4. Serial 12-hour Fev1 On The First Day And At Week 12 Of Treatment (42aa9a5a C1f5 41ae Ba72 E9a46db63786 06)

Figure 4. Serial 12-hour Fev1 On The First Day And At Week 12 Of Treatment (42aa9a5a C1f5 41ae Ba72 E9a46db63786 06)
FDA Label Image

Pil Parts Figure (42aa9a5a C1f5 41ae Ba72 E9a46db63786 07)

Pil Parts Figure (42aa9a5a C1f5 41ae Ba72 E9a46db63786 07)
FDA Label Image

Pil Figure 1 (42aa9a5a C1f5 41ae Ba72 E9a46db63786 08)

Pil Figure 1 (42aa9a5a C1f5 41ae Ba72 E9a46db63786 08)
FDA Label Image

Pil Figure 2 (42aa9a5a C1f5 41ae Ba72 E9a46db63786 09)

Pil Figure 2 (42aa9a5a C1f5 41ae Ba72 E9a46db63786 09)
FDA Label Image

Pil Figure 3 (42aa9a5a C1f5 41ae Ba72 E9a46db63786 10)

Pil Figure 3 (42aa9a5a C1f5 41ae Ba72 E9a46db63786 10)
FDA Label Image

Pil Figure 4 (42aa9a5a C1f5 41ae Ba72 E9a46db63786 11)

Pil Figure 4 (42aa9a5a C1f5 41ae Ba72 E9a46db63786 11)
FDA Label Image

Pil Figure 5 (42aa9a5a C1f5 41ae Ba72 E9a46db63786 12)

Pil Figure 5 (42aa9a5a C1f5 41ae Ba72 E9a46db63786 12)
FDA Label Image

Pil Figure 6 (42aa9a5a C1f5 41ae Ba72 E9a46db63786 13)

Pil Figure 6 (42aa9a5a C1f5 41ae Ba72 E9a46db63786 13)
FDA Label Image

Ndc 68258-8961-06 (Ndc 68258 8961 06 Glaxosmithkline)

Ndc 68258-8961-06 (Ndc 68258 8961 06 Glaxosmithkline)
This document contains information on a medication called SEREVENT DISKUS, manufactured by GlaxoSmithKline. It is an inhalation powder and comes in a package with teal, white, yellow, black, and orange colors, and the product ID is NDC 0173-0521-00. The document provides details on the product's dosage, manufacturer lot, and dispensing information. It is recommended to read the medication guide provided with the package, and the powder should be discarded six weeks after removal from the overwrap. This document also warns to keep the medication out of children's reach and store it at 68°- 77° F.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.